5.28
2.52%
0.13
After Hours:
5.26
-0.02
-0.38%
Corvus Pharmaceuticals Inc stock is traded at $5.28, with a volume of 114.46K.
It is up +2.52% in the last 24 hours and up +17.86% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$5.15
Open:
$5.16
24h Volume:
114.46K
Relative Volume:
0.31
Market Cap:
$330.27M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-6.2857
EPS:
-0.84
Net Cash Flow:
$-23.97M
1W Performance:
-2.94%
1M Performance:
+17.86%
6M Performance:
+196.63%
1Y Performance:
+261.64%
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-18-23 | Initiated | Oppenheimer | Outperform |
Dec-01-21 | Resumed | Jefferies | Buy |
May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
Sep-12-19 | Initiated | Mizuho | Buy |
May-29-19 | Initiated | ROTH Capital | Buy |
Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
Apr-18-16 | Initiated | Credit Suisse | Outperform |
Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals (NASDAQ:CRVS) Downgraded to "Sell" at StockNews.com - MarketBeat
When the Price of (CRVS) Talks, People Listen - Stock Traders Daily
Croda International (OTCMKTS:COIHD) Sets New 52-Week Low at $26.75 - Defense World
Cormorant Asset Management's Strategic Acquisition in Corbus Pha - GuruFocus.com
Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week High at $43.81 - Defense World
Cormorant asset management buys $7m in Corbus Pharmaceuticals stock By Investing.com - Investing.com Canada
Closing Figures Unveiled: Corvus Pharmaceuticals Inc (CRVS) Drop -7.95, Closes at 5.44 - The Dwinnex
A stock that deserves closer examination: Corvus Pharmaceuticals Inc (CRVS) - US Post News
Are Smart Investors Making the Right Decision? Corbus Pharmaceuticals Holdings Inc (CRBP) - SETE News
Top investors say Corcept Therapeutics Inc (CORT) ticks everything they need - SETE News
Samlyn Capital LLC Has $11.14 Million Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Wall Street Analyst Initiated Core Scientific Inc [CORZ]. What else is Wall St. saying - The DBT News
Where are the Opportunities in (CRBP) - Stock Traders Daily
Corcel shares drop as explorer raise funds and ups exposure in Angola - Proactive Investors USA
Corvus Pharmaceuticals Inc [CRVS] Stock bought by Insider Jones William Benton for $34624.0 - Knox Daily
Integral Health Asset Management LLC Invests $4.53 Million in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Spotlight on Corbus Pharmaceuticals: Analyzing the Surge in Options Activity - Benzinga
Evergreen Capital Management LLC Purchases 1,441 Shares of Coterra Energy Inc. (NYSE:CTRA) - Defense World
How does CRBP’s price to cash per share ratio compare in the market? - US Post News
There is no way Corsair Gaming Inc (CRSR) can keep these numbers up - SETE News
Mizuho recommends buying Corbus following its drop post-Novo's obesity data (NASDAQ:CRBP) - Seeking Alpha
450,000 Shares in Core Scientific, Inc. (NASDAQ:CORZ) Bought by P Schoenfeld Asset Management LP - MarketBeat
Core Scientific (NASDAQ:CORZ) Coverage Initiated at Canaccord Genuity Group - Defense World
Hancock Whitney Corp Has $737,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Core Scientific (NASDAQ:CORZ) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat
Ratios in Focus: Analyzing Corbus Pharmaceuticals Holdings Inc (CRBP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Discovery Capital Management LLC CT Decreases Position in Credo Technology Group Holding Ltd (NASDAQ:CRDO) - MarketBeat
Sompo Asset Management Co. Ltd. Has $588,000 Stock Holdings in Copart, Inc. (NASDAQ:CPRT) - Defense World
Symmetry Investments LP Invests $465,000 in Core Scientific, Inc. (NASDAQ:CORZ) - Defense World
Summit Trail Advisors LLC Takes $6.46 Million Position in Core Scientific, Inc. (NASDAQ:CORZ) - Defense World
Core Scientific (NASDAQ:CORZ) Sets New 52-Week High at $12.55 - Defense World
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks - Nasdaq
Corbus Pharmaceuticals (NASDAQ:CRBP) Receives “Outperform” Rating from Royal Bank of Canada - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) PT Lowered to $40.00 at B. Riley - Defense World
Corcept Therapeutics Inc [CORT] Shares Fall -3.19 % on Thursday - Knox Daily
Corbus Pharmaceuticals price target lowered to $40 from $85 at B. Riley - TipRanks
Corbus Pharmaceuticals (NASDAQ:CRBP) Given New $51.00 Price Target at Wedbush - MarketBeat
Skye Bioscience, Corbus sink after Novo weight loss data - TipRanks
Corbus stock reiterates Outperform rating despite trial data - Investing.com
Corbus drops after rival Novo Nordisk reports obesity drug data - XM
Bank of New York Mellon Corp Takes $1.37 Million Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
XTX Topco Ltd Purchases 33,656 Shares of Copart, Inc. (NASDAQ:CPRT) - Defense World
Credo Technology Group (NASDAQ:CRDO) Shares Up 5.6% - MarketBeat
Analyzing the Impact of Earnings Reports on Corcept Therapeutics Inc Inc. (CORT) Price Performance - The InvestChronicle
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last? - Yahoo Finance
A look at CORT’s current quarter earnings estimates - US Post News
Corvus Pharmaceuticals Inc (CRVS) presents a great opportunity, but the stock is slightly undervalued - US Post News
Daily Market Movement: Core Scientific Inc (CORZ) Sees a 2.68 Increase, Closing at 11.48 - The Dwinnex
Corvus Pharmaceuticals Inc (CRVS) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Corvus Pharmaceuticals (NASDAQ:CRVS) PT Raised to $21.00 - MarketBeat
Prepare Yourself for Liftoff: Corvus Pharmaceuticals Inc (CRVS) - SETE News
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):